It compounds what it sells
The homepage says the medication is compounded in the company's own Austin pharmacy, names an accreditation, and puts a trademarked slogan about making it themselves on the page.
Two hundred and twenty-one of the two hundred and sixty-four sellers here name no compounding pharmacy at all, and a reader has no way to find out which one. This is the opposite arrangement, and it is the strongest thing about the row.
Flat at every dose, and two rates side by side
The plan is advertised as flat-rate pricing no matter the dose. Dose-banded pricing is the standard way a headline figure here stops being true once a patient titrates up, and this seller rules it out in its own words.
Two figures are printed together: one with no contract and a lower one on a six-month plan. Showing both is the honest way to advertise a commitment discount, and it is not the common practice.
The plan block is headed as all-included, and the programme index says each programme includes provider-led care, the medication and ongoing support. No separate fee appears anywhere we read.
And it never names the drug
The product is called a full-strength GLP-1. That is the whole description. Neither semaglutide nor tirzepatide appears on either page we read.
So a buyer is being offered a flat price at every dose for a molecule that is not identified, and we file the figure under an unspecified GLP-1 rather than guessing. A dual-incretin combination and a plain GLP-1 are different drugs at different prices everywhere else on this roster.
A letter that belongs to somebody else
Searching the FDA's live warning-letter table for this company's name returns exactly one result, and it is a tobacco importer with a similar name. It has nothing to do with this business, and it is not recorded against this row.
It is worth writing down because a name-keyed screen would have attached it. Reading the letter's subject is what stops a coincidence becoming a disclosure.
Its headline outcome claim carries no sample size or method. It names no prescribing clinician and publishes no state list. Two of its four programmes are marked sold out or coming soon.
Nimbus Healthcare's published pricing
| Medication | Price | Verified |
|---|---|---|
| Glp-1 (compounded) | $179/mofrom, per month, with no contract — the homepage reads "WeightWise rx GLP-1 Plan. Flat rate pricing. No matter the dose. From $179/mo, no contract, refill when you're ready." ⛔ The product names no molecule anywhere we read: it is described only as a "Full strength GLP-1", so this figure is filed under an unspecified GLP-1 | September 2026source |
| Glp-1 (compounded) | $129/mothe lower rate, conditioned on a six-month commitment in the seller's own words — "Or $129/mo on the 6-month plan" — printed immediately after the no-contract figure. Same unnamed molecule | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 264 providers reviewed here are paid partners today; the other 260 are not. See how this works.
See Nimbus Healthcare's current price →Good fit if
- Buyers who want to know exactly who compounds their medication.
- Readers who want one price at every dose, stated as such.
- People weighing a six-month commitment against a month-to-month one with both figures in front of them.
Look elsewhere if
- Anyone who needs to know which molecule they are buying.
- Readers who want a brand-name option.
- Buyers who need their state confirmed or a prescriber named.
- People who weigh an outcome statistic by the sample behind it.
How this review was verified
- Read the homepage and the programme index on 7 September 2026, comparing requested to effective URLs, with a nonsense path on the same host in the same run, which returned a 404.
- Recorded both the no-contract figure and the six-month figure from the same sentence, with the commitment attached to the lower one.
- Searched both pages for a molecule name and found none, and filed the figures under an unspecified GLP-1 rather than inferring one.
- Searched the live FDA warning-letter table for this company's name, read the single result's subject line, and refused it as a different company rather than attaching it.
- Confirmed a positive control returning exactly one row and a nonsense control returning none in the same FDA run.